141 related articles for article (PubMed ID: 37932653)
1. Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy.
Zhang W; Yang C; Zou L; Zang Y; Hu J; Hu Y; Xu C; Liu R; Wang H; Xiong Z
J Appl Genet; 2024 Feb; 65(1):103-112. PubMed ID: 37932653
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.
Zeng Y; Tian X; Wang Q; He W; Fan J; Gou X
Drug Des Devel Ther; 2018; 12():911-920. PubMed ID: 29719377
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
[TBL] [Abstract][Full Text] [Related]
4. Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model.
Avniel-Polak S; Leibowitz G; Doviner V; Gross DJ; Grozinsky-Glasberg S
Endocr Relat Cancer; 2018 Jun; 25(6):677-686. PubMed ID: 29636368
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
[TBL] [Abstract][Full Text] [Related]
7. Protective Autophagy Attenuates the Cytotoxicity of MTI-31 in Renal Cancer Cells by Activating the ERK Pathway.
Zang Y; Yang C; Dai MS; Zhang W; Zou L; Hu J; Hu Y; Xu C; Liu R; Wang H; Xiong Z
Appl Biochem Biotechnol; 2024 Apr; 196(4):2233-2245. PubMed ID: 37493819
[TBL] [Abstract][Full Text] [Related]
8. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
Song L; Liu S; Zhao S
Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
[TBL] [Abstract][Full Text] [Related]
9. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
10. [Everolimus combined with all-trans retinoid acid reverses drug resistance in acute promyelocytic leukemia NB4-R1 cells].
Liao WC; He Y; Wang BS; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 44(5):525-31. PubMed ID: 26713527
[TBL] [Abstract][Full Text] [Related]
11. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
12. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
Ji D; Zhang Z; Cheng L; Chang J; Wang S; Zheng B; Zheng R; Sun Z; Wang C; Zhang Z; Liu R; Zhang X; Liu X; Wang X; Li J
PLoS One; 2014; 9(1):e85116. PubMed ID: 24416349
[TBL] [Abstract][Full Text] [Related]
13. Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
Tai S; Xu L; Xu M; Zhang L; Zhang Y; Zhang K; Zhang L; Liang C
Oncotarget; 2017 Feb; 8(7):11206-11218. PubMed ID: 28061438
[TBL] [Abstract][Full Text] [Related]
14. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
[TBL] [Abstract][Full Text] [Related]
15. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
[TBL] [Abstract][Full Text] [Related]
16. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells.
Tai S; Sun Y; Liu N; Ding B; Hsia E; Bhuta S; Thor RK; Damoiseaux R; Liang C; Huang J
Mol Cancer Ther; 2012 Jun; 11(6):1320-31. PubMed ID: 22491797
[TBL] [Abstract][Full Text] [Related]
17. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
18. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
19. The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2.
Chao A; Lin CY; Wu RC; Lee YS; Lee LY; Tsai CL; Yang LY; Liu H; Chen SJ; Wang TH; Lai CH
J Mol Med (Berl); 2018 Nov; 96(11):1251-1266. PubMed ID: 30298385
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.
Grimaldi A; Santini D; Zappavigna S; Lombardi A; Misso G; Boccellino M; Desiderio V; Vitiello PP; Di Lorenzo G; Zoccoli A; Pantano F; Caraglia M
Cancer Biol Ther; 2015; 16(4):567-79. PubMed ID: 25866016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
